LumiraDx’s mission is to transform community-based healthcare through point of care (POC) diagnostics and make lab-comparable tests accessible to all.
LumiraDx is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, the company manufactures and commercialises an innovative diagnostic Platform that supports a broad menu of tests with lab-comparable performance at the point of care.
LumiraDx’s diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. The point of care Platform provides vital lab solutions to countries without laboratory infrastructure.
LumiraDx is a UK-based company with over 1,600 employees worldwide.
Elevating healthcare pathways and improving patient outcomes
LumiraDx’s innovative POC Platform supports a broad menu of cost-effective tests with lab-comparable performance and results available in minutes. It is intuitively designed for trained users and has the capability to be used in an extensive range of environments. Whether that’s in hospitals, medical offices, pharmacies, or in non-traditional settings such as schools, airports, or workplaces.
The company has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need. Rapid, accurate COVID-19 tests – and the Amira mass screening and home testing system that is in development – are playing a fundamental role in unlocking society and the economy from the COVID-19 pandemic. Its SARS-CoV-2 Antigen test serves as a powerful proof point for the impact of microfluidic immunofluorescence technology. This next-generation point of care technology will rapidly scale up lab-comparable testing with fast results across health conditions and testing environments.
Delivering tests through a single, easy-to-use, cost-efficient Platform
LumiraDx is developing point of care tests with lab-comparable performance for 30+ common conditions, including infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The current tests available in the LumiraDx portfolio include the high sensitivity SARS-CoV-2 Antigen, Antibody and Pool tests, SARS-CoV-2 & Flu A/B Antigen, INR, D-Dimer and CRP. In addition, the company is developing tests for Strep A, HbA1c, high sensitivity troponin I, and TB. The future panel of 30+ tests on a single platform will transform the quality and accessibility of diagnostic care.